Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3216893
Max Phase: Preclinical
Molecular Formula: C26H32BrCl2N5O4
Molecular Weight: 556.46
Molecule Type: Small molecule
Associated Items:
ID: ALA3216893
Max Phase: Preclinical
Molecular Formula: C26H32BrCl2N5O4
Molecular Weight: 556.46
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cl.Cl.O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\OCCN1CCN(CCOCCO)CC1
Standard InChI: InChI=1S/C26H30BrN5O4.2ClH/c27-18-5-6-19-22(17-18)29-26(34)23(19)25-24(20-3-1-2-4-21(20)28-25)30-36-15-12-32-9-7-31(8-10-32)11-14-35-16-13-33;;/h1-6,17,28,33H,7-16H2,(H,29,34);2*1H/b25-23-,30-24+;;
Standard InChI Key: QKKQNWWTERHAMS-RXGHSYFKSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 556.46 | Molecular Weight (Monoisotopic): 555.1481 | AlogP: 2.59 | #Rotatable Bonds: 9 |
Polar Surface Area: 98.66 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 3 |
#RO5 Violations: 1 | HBA (Lipinski): 9 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 10.61 | CX Basic pKa: 7.33 | CX LogP: 2.07 | CX LogD: 1.80 |
Aromatic Rings: 2 | Heavy Atoms: 36 | QED Weighted: 0.25 | Np Likeness Score: -0.29 |
1. Vougogiannopoulou K, Ferandin Y, Bettayeb K, Myrianthopoulos V, Lozach O, Fan Y, Johnson CH, Magiatis P, Skaltsounis AL, Mikros E, Meijer L.. (2008) Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period., 51 (20): [PMID:18816110] [10.1021/jm800648y] |
2. Gaboriaud-Kolar N, Myrianthopoulos V, Vougogiannopoulou K, Gerolymatos P, Horne DA, Jove R, Mikros E, Nam S, Skaltsounis AL.. (2016) Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines., 79 (10): [PMID:27726390] [10.1021/acs.jnatprod.6b00285] |
Source(1):